Reverse DCF
What growth does the market imply for MEDPLUS?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
10.8% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹873
Historical Growth
5.0%
FCF Yield
3.55%
Price / FCF
28.2x
Plain English
To justify today's price of ₹872.85, MEDPLUS.NS needs to grow its free cash flow at 10.8% per year for the next 10 years. That is 5.8% faster than its historical growth rate of 5.0%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 5.0% | ₹522 | -40.2% |
| Half implied | 5.4% | ₹541 | -38.0% |
| GDP rate | 10.0% | ₹821 | -6.0% |
| Implied | 10.8% | ₹873 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 5.0% growth, the model values MEDPLUS at ₹522, below today's ₹873.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.